Patents by Inventor Ted William Johnson
Ted William Johnson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11142525Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.Type: GrantFiled: November 11, 2019Date of Patent: October 12, 2021Assignee: PFIZER INC.Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He, Anne-Marie Dechert Schmitt
-
Publication number: 20200172539Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R1a, R2, R3, R4, and (R5)a are as defined herein, to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable salts thereof, and to methods of using such compounds, pharmaceutically acceptable salts and compositions for the treatment of abnormal cell growth, including cancer.Type: ApplicationFiled: November 11, 2019Publication date: June 4, 2020Applicant: Pfizer Inc.Inventors: Rebecca Anne Gallego, Sajiv Krishnan Nair, Robert Steven Kania, Omar Khaled Ahmad, Ted William Johnson, Jamison Bryce Tuttle, Mehran Jalaie, Michele Ann McTigue, Dahui Zhou, Matthew L. Del Bel, Ru Zhou, Mingying He
-
Patent number: 9593097Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: GrantFiled: December 14, 2015Date of Patent: March 14, 2017Assignee: Pfizer Inc.Inventors: Ted William Johnson, Paul Francis Richardson, Michael Raymond Collins, Daniel Tyler Richter, Benjamin Joseph Burke, Sacha Ninkovic, Ketan Satish Gajiwala, Maria Angelica Linton, Phuong Thi Quy Le, Jacqui Elizabeth Hoffman
-
Publication number: 20160176850Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.Type: ApplicationFiled: December 14, 2015Publication date: June 23, 2016Inventors: Ted William Johnson, Paul Francis Richardson, Michael Raymond Collins, Daniel Tyler Richter, Benjamin Joseph Burke, Sacha Ninkovic, Ketan Satish Gajiwala, Maria Angelica Linton, Phuong Thi Quy Le, Jacqui Elizabeth Hoffman
-
Patent number: 9133215Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.Type: GrantFiled: January 15, 2014Date of Patent: September 15, 2015Assignee: Pfizer Inc.Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
-
Patent number: 8916593Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.Type: GrantFiled: May 4, 2011Date of Patent: December 23, 2014Assignee: Pfizer Inc.Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
-
Patent number: 8791131Abstract: The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-K? inhibitors and/or PI3-K?/mTOR dual inhibitors.Type: GrantFiled: September 18, 2009Date of Patent: July 29, 2014Assignee: Pfizer Inc.Inventors: Hengmiao Cheng, Ted William Johnson, Jacqui Elizabeth Hoffman, Lisa Chen Guo, Zhengyu Liu
-
Publication number: 20140135339Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.Type: ApplicationFiled: January 15, 2014Publication date: May 15, 2014Applicant: PFIZER INC.Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
-
Patent number: 8680111Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.Type: GrantFiled: March 5, 2013Date of Patent: March 25, 2014Assignee: Pfizer Inc.Inventors: Simon Bailey, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
-
Publication number: 20130252961Abstract: The invention relates to compounds of formula (?) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.Type: ApplicationFiled: March 5, 2013Publication date: September 26, 2013Applicant: PFIZER INC.Inventors: Simon BAILEY, Benjamin Joseph Burke, Michael Raymond Collins, Jingrong Jean Cui, Judith Gail Deal, Robert Louis Hoffman, Qinhua Huang, Ted William Johnson, Robert Steven Kania, John Charles Kath, Phuong Thi Quy Le, Michele Ann McTigue, Cynthia Louise Palmer, Paul Francis Richardson, Neal William Sach
-
Publication number: 20130196952Abstract: The invention relates to compounds of Formula (1) and to processes for the preparation of intermediates used in the preparation of compositions containing and the uses of such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.Type: ApplicationFiled: May 4, 2011Publication date: August 1, 2013Applicant: PFIZER INC.Inventors: Mark Edward Bunnage, Andrew Simon Cook, Jingrong Jean Cui, Kevin Nell Dack, Judith Gail Deal, Danlin Gu, Mingying He, Patrick Stephen Johnson, Ted William Johnson, Phuong Thi Quy Le, Cynthia Louise Palmer, Hong Shen
-
Publication number: 20110190326Abstract: The present invention is directed to compounds of Formula (I), and to salts thereof, their synthesis, and their use as PI3-K? inhibitors and/or PI3-K?/mTOR dual inhibitors.Type: ApplicationFiled: September 18, 2009Publication date: August 4, 2011Inventors: Hengmiao Cheng, Ted William Johnson, Jacqui Elizabeth Hoffman, Lisa Chen Guo, Zhengyu Liu
-
Publication number: 20100137283Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.Type: ApplicationFiled: February 1, 2010Publication date: June 3, 2010Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Huichun Zhu, Junhu Zhang
-
Patent number: 7692014Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.Type: GrantFiled: April 25, 2005Date of Patent: April 6, 2010Assignee: Pfizer, Inc.Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Huichun Zhu, Junhu Zhang
-
Publication number: 20090170846Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus “HIV” integrase enzyme. Formula (I).Type: ApplicationFiled: September 22, 2006Publication date: July 2, 2009Inventors: Klaus Ruprecht Dress, Michael Bruno Plewe, Ted William Johnson, Steven Paul Tanis, Khanh Tuan Tran
-
Patent number: 7468375Abstract: The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.Type: GrantFiled: April 25, 2005Date of Patent: December 23, 2008Assignee: Pfizer Inc.Inventors: Klaus Ruprecht Dress, Qiyue Hu, Ted William Johnson, Michael Bruno Plewe, Steven Paul Tanis, Hai Wang, Anle Yang, Chunfeng Yin, Junhu Zhang
-
Publication number: 20080221154Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.Type: ApplicationFiled: March 6, 2008Publication date: September 11, 2008Inventors: Qiyue HU, Ted William Johnson, Atsuo Kuki, Michael Bruno Plewe, Dawn Marie Nowlin, Hai Wang, Junhu Zhang
-
Patent number: 7135482Abstract: Bicyclic hydroxamate compounds represented by the Formula I: are described. The bicyclic hydroxamate compounds and compositions containing those compounds may be used to inhibit or modulate an enzyme activity of HIV Integrase and to treat HIV mediated diseases and conditions.Type: GrantFiled: October 30, 2003Date of Patent: November 14, 2006Assignee: Agouron Pharmaceuticals, Inc.Inventors: Qiyue Hu, Ted William Johnson, Atsuo Kuki, Michael Bruno Plewe, Dawn Marie Nowlin, Hai Wang, Junhu Zhang
